Semaglutide is a long-acting GLP-1 receptor agonist peptide analog structurally modified with a C18 fatty diacid chain to extend plasma half-life. It is commonly studied for its interactions with glucagon-like peptide-1 receptors and their downstream effects on metabolic signaling pathways.
- Commonly studied for its role in GLP-1 receptor binding kinetics and intracellular cAMP signaling cascades
- Associated with research into pancreatic beta-cell function, insulin secretion modeling, and glucose homeostasis
- May support research into appetite-regulating neuropeptide pathways and hypothalamic signaling
- Observed in studies examining lipid metabolism, hepatic glucose output, and adipocyte biology
- Frequently referenced in obesity and type 2 diabetes metabolic pathway research
For Research Use Only. This compound is intended exclusively for in-vitro laboratory research by qualified investigators. It is not intended for human or animal consumption, is not a pharmaceutical product, and has not been evaluated by the FDA for safety or efficacy.
Sequence: GLP-1 analogue with C18 fatty acid chain
